LongeVC managing partner Sergey Jakimov joined Chris Patil on the Translating Aging podcast, produced by BioAge Labs, to share how our investment strategy reflects the evolution of the longevity biotech market. The discussion focused on the shift toward disease-focused, clinically validated solutions and what pharma’s growing appetite means for the future of healthspan innovation.
Sergey also shared lessons from recent partnerships involving our portfolio companies, including Rubedo Life Sciences’ collaboration with Beiersdorf and Turn Biotechnologies’ $300M deal with HanAll Biopharma, and explained why LongeVC continues to back early-stage companies with strong IP and balanced teams.